/ /

  • linkedin
  • Increase Font
  • Sharebar

    Binkhorst Lecture: Right time for MIGS


    Numerous studies are ongoing in the United States and internationally of various stenting devices—such as the trabecular micro-bypass device, CyPass Microstent, Transcend Medical; and the Hydrus II, Ivantis—with more than 1,000 patients with glaucoma participating. Implantation of single and multiple devices at strategic locations are being investigated.

    When considering the spectrum of treatments for glaucoma, MIGS falls between medications and lasers, and should prove to be safer and more efficacious than the previous go-to interventions, he noted.

    “MIGS is the future of treatment for glaucoma,” Dr. Ahmed said. “This approach will allow early intervention and decrease glaucoma progression. This is the new horizon for patients.

    “Interventional glaucoma is not just about IOP, it is about the patient and the quality of their lives,” he continued. “MIGS is an idea whose time has come. It makes sense. Nothing will stop this.”

    For more articles in this issue of Ophthalmology Times’ Conference Brief, click here.



    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results